Citizens Upgrades Quince Therapeutics to Market Outperform, Announces $77 Price Target

Citizens analyst Jonathan Wolleben has upgraded Quince Therapeutics (NASDAQ: QNCX) from Market Perform to Market Outperform. Additionally, a price target of $77 has been announced for the stock.